Thérapie par cellules souches: A Novel Approach for Early-Stage Chronic Kidney Disease
Chronic kidney disease (MRC) is a global health concern, affecting millions worldwide. Current treatment options for CKD are limited, and most patients eventually progress to end-stage renal disease (ESRD) requiring dialysis or transplantation. Thérapie par cellules souches has emerged as a promising approach for treating early-stage CKD, offering the potential to repair damaged kidney tissue and restore function.
Exploring the Potential of Stem Cells in Kidney Repair
Stem cells are undifferentiated cells that have the ability to develop into various specialized cell types. In the context of CKD, stem cells can be derived from various sources, y compris la moelle osseuse, tissu adipeux, and the kidneys themselves. These stem cells can be directed to differentiate into functional kidney cells, such as podocytes and tubular epithelial cells, which are crucial for kidney function. By replacing damaged or lost kidney cells, stem cells can potentially restore kidney function and slow or halt the progression of CKD.
